Bristol-myers: (NYSE: BMY)
$43.30
0.53 (1.24%)
Volume 11,059,814
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 42.70 - 43.43 |
| 52wk Low - High | 30.64 - 45.59 |
| Previous Close | 42.77 |
| Avg. Volume | 11,156,058 |
| Industry | LARGE CAP PHARMA |
| Market Cap | 71.14 B |
| Div - Yield | 1.40 - 3.23 |
| Beta | 0.45 |
| PE (Forward) | 23.92 |
| Current Year Est. | 1.81 |
| Quarterly Earnings ESP |
-2.22% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
170 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 23.92 |
| PEG Ratio | 4.41 |
| Current Year Est. | 1.81 |
| Current Quarter Estimate | 0.45 |
| Most Accurate Estimate | 0.44 |
| Earnings ESP |
-2.22% |
| Next Earnings Report Date | 07-24-2013 |
| EPS Last Year | 1.73 |
| Expected Earnings Growth | 5.42% |
Company Description
Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.45 | 0.46 | 1.81 | 2.13 |
| Number of Estimates | 9 | 8 | 12 | 10 |
| Low Estimate | 0.43 | 0.44 | 1.78 | 1.93 |
| High Estimate | 0.49 | 0.48 | 1.86 | NA |
| Year Ago EPS | 0.48 | 0.37 | 1.99 | 1.81 |
| EPS Growth | -6.25% | 24.32% | -9.05% | 17.73% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| BRISTOL-MYERS | BMY | 43.30 | |
|
| ABBOTT LABS | ABT | 36.59 | |
|
| ABBVIE INC | ABBV | 47.17 | |
|
| ALLERGAN INC | AGN | 101.41 | |
|
| ASTRAZENECA PLC | AZN | 51.56 | |
|
| BAYER A G -ADR | BAYRY | 108.13 | |
|
| GLAXOSMITHKLINE | GSK | 52.22 | |
|
| JOHNSON & JOHNS | JNJ | 88.09 | |
|
| LILLY ELI & CO | LLY | 55.90 | |
|
| MERCK & CO INC | MRK | 45.99 | |
|
Sector:Medical>> Industry:LARGE CAP PHARMA
COMPARE TICKER vs. Its Peers
Zacks Commentary
Pediatric Approval for MDCO/BMY's Recothrom
May 15, 2013
Amgen to Set Up JV in China
May 14, 2013
Simcere Beats 1Q Earnings & Revenue Estimate
May 10, 2013
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus
May 07, 2013
Good News for Bristol-Myers
May 06, 2013
Narrower-than-Expected Loss at Cadence
May 06, 2013
Stocks Market News for May 1, 2013
May 01, 2013
Earnings Increase at The Medicines Co.
Apr 26, 2013
Financials
| EPS TTM | 1.73 |
| Sales | 17,621 |
| Net Income | 1,468 |
| Price/Earnings | 25.03 |
| Price/Book | 5.19 |
| Price/Cash Flow | 17.67 |
| Price/Sales | 4.39 |
News
1 Giant Leap for MannKind - TheMotleyFool
May 18, 2013
Pick Your Poison: Overweight or High Cholesterol - TheMotleyFool
May 18, 2013
Analysts` Actions: AMAT ARUN BMY DE WSM - TheStreet.com
May 17, 2013
Bristol-Myers Squibb to voluntarily delist Preferred Stock from NYSE - M2
May 17, 2013
Cancer cocktail shows promise - Investors Business Daily
May 17, 2013
Quick Take: The Next Big Thing in Biotech - TheStreet.com
May 17, 2013
5 Stock Trades for S&P 1,700 - TheStreet.com
May 16, 2013
Ambrx collaborates with Bristol-Myers to develop antibody drug conjugates - Datamonitor
May 16, 2013
Broker Recommendations
| Current ABR | 2.48 |
| ABR (Last Week) | 2.48 |
| # of recs in ABR | 21 |
| Average Target Price | 38.75 |
| Industry Rank by ABR | 170 out of 265 |
| Rank in Industry | 1 out of 15 |
